Key Highlights

  • 351.3 million is the USD cash, cash equivalents and investments balance of MapLight Therapeutics, Inc. (NASDAQ:MPLT) at June 30, 2026, down from USD 453.1 million at December 31, 2025, before a USD 150 million private placement.
  • 60.2 million is the USD net loss reported for the second quarter of 2026, or USD 1.32 per share, compared with USD 29.8 million a year earlier, as Research and Development expense rose to USD 53.4 million.
  • 2028 is the year through which cash plus net Placement proceeds is expected to fund ML-007C-MA, including the VISTA readout in the second half of 2027.
  • 210/3 mg twice daily is the dose of ML-007C-MA that met the primary endpoint in the Phase 2 ZEPHYR schizophrenia trial in July 2026, a result central to MapLight Therapeutics, Inc. (NASDAQ:MPLT).

What Investors Expect From MapLight Therapeutics, Inc. (NASDAQ:MPLT) on November 16, 2026

MapLight Therapeutics, Inc. (NASDAQ:MPLT), a clinical-stage biopharmaceutical company, is scheduled to report third quarter 2026 results on November 16, 2026. In the second quarter, research and development expense was USD 53.4 million against USD 26.8 million a year earlier, and general and administrative expense was USD 10.1 million against USD 3.8 million. For the six months, R&D was USD 107.1 million and the net loss USD 120.9 million, so the third quarter will show whether spending is stabilizing after the ZEPHYR readout.

The Rationale: Last Reported Quarter and Management Outlook for MapLight Therapeutics, Inc. (NASDAQ:MPLT)

Second quarter net loss was USD 60.2 million, or USD 1.32 per share, on weighted average shares of 45,431,359, and interest income was USD 2.3 million. The pipeline update was mixed. ML-007C-MA delivered positive Phase 2 ZEPHYR topline results in schizophrenia in July 2026, with the 210/3 mg twice-daily dose meeting the primary PANSS endpoint at Week 5, while the ML-004 IRIS trial in autism missed its primary social communication endpoint in June 2026, although a prespecified adolescent subgroup showed clinically meaningful improvement in irritability. A Phase 3 ZEPHYR-2 trial is planned pending an End-of-Phase 2 meeting with the FDA, with topline results expected in 2028.

Valuation, Liquidity and Risks for MapLight Therapeutics, Inc. (NASDAQ:MPLT)

Stockholders' Equity was USD 348.3 million at June 30, 2026. In August 2026 the company announced a USD 150 million private placement with new and existing institutional investors and said it would pause preclinical and discovery-stage programs to concentrate on ML-007C-MA. Management expects cash plus net proceeds to fund the program through the end of 2028. Risks include the outcome of the End-of-Phase 2 FDA meeting, the cost of a Phase 3 trial, the VISTA trial in Alzheimer's disease psychosis, which is enrolling about 300 participants, and the need for partnerships or other funding for the autism program.

Where Things Stand

MapLight Therapeutics, Inc. (NASDAQ:MPLT) reports on November 16, 2026 after a quarter that changed its clinical profile. The ZEPHYR schizophrenia trial met its primary endpoint in July 2026, the company secured a USD 150 million private placement in August 2026, and cash of USD 351.3 million at June 30, 2026 now has an expected runway through the end of 2028. Quarterly spending is the key measure, with a second quarter net loss of USD 60.2 million. The report should update regulatory plans for ZEPHYR-2, the VISTA enrollment timeline for a second half 2027 readout, and the strategy for ML-004.